AELIS FARMA: management transactions · France · AMF

About AELIS FARMA

Aelis Farma is a French biotechnology company listed on Euronext Paris, focused on the discovery and development of drug candidates for central nervous system disorders. The company is known for a distinctive scientific approach based on the selective modulation of CB1 cannabinoid receptors, an avenue of research derived from the work of co-founder and CEO Dr. Pier Vincenzo Piazza at the Neurocentre Magendie of INSERM in Bordeaux. The company’s headquarters and laboratory footprint are rooted in the Bordeaux area, and more recently it has consolidated its staff and facilities in Pessac, reinforcing its presence in one of France’s main life-science clusters. Aelis Farma was created around this academic and translational expertise and reached a major milestone with its listing on the regulated market of Euronext Paris in February 2022. The IPO marked the transition from a research-driven private structure to a publicly listed clinical-stage biopharmaceutical company. Since then, the group has focused on advancing its pipeline while building visibility in the French and international biotech investment universe. Its history is therefore closely tied to the conversion of breakthrough neuroscience research into therapeutic development. The company’s pipeline currently centers on two main clinical programs. AEF0117 is being developed for cannabis-related disorders, including severe dependence, acute psychosis, and acute toxicity. AEF0217 targets cognitive deficits and related disorders, including Down syndrome, Fragile X syndrome, subjective memory impairment, and potentially Alzheimer’s disease. Aelis Farma has highlighted positive Phase 1/2 data for AEF0217, including a favorable safety and pharmacokinetic profile as well as statistically significant improvements in adaptive behaviors and brain activity in young adults with Down syndrome. From a market standpoint, Aelis Farma remains a small-cap biotech with no meaningful commercial revenues yet, and its valuation depends heavily on clinical execution, regulatory progress, and access to financing. Its strategic positioning is that of a specialist company operating in high-unmet-need neurological and psychiatric indications, where differentiation through mechanism of action can be highly valuable if translated successfully into efficacy and safety outcomes. Like most clinical-stage biopharma companies, it has a long development horizon, high R&D intensity, and periodic capital market needs to fund trials and corporate operations. Notable recent developments include the company’s 2025 operational refocusing around its Pessac laboratories and its continued emphasis on advancing its core programs. Overall, Aelis Farma represents a French biotech built on public-research origins, combining neuroscience innovation, clinical ambition, and capital markets exposure in a single equity story.